Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
5,292,741
-
Share change
-
+220,437
-
Total reported value
-
$31,281,000
-
Price per share
-
$5.91
-
Number of holders
-
26
-
Value change
-
+$1,377,333
-
Number of buys
-
15
-
Number of sells
-
11
Institutional Holders of CATABASIS PHARMACEUTICALS IN - COM NEW as of Q4 2019
As of 31 Dec 2019,
CATABASIS PHARMACEUTICALS IN - COM NEW was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,292,741 shares.
The largest 10 holders included
FEDERATED HERMES, INC., Corriente Advisors, LLC, VANGUARD GROUP INC, Samsara BioCapital, LLC, SV Health Investors, LLC, DIMENSIONAL FUND ADVISORS LP, BlackRock Inc., Blackstone Group Inc, Alyeska Investment Group, L.P., and OXFORD ASSET MANAGEMENT LLP.
This page lists
26
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.